GALLANT 4 Tesaglitazar vs. Glibenclamide
A 52-Week Randomized, Double-Blind, Parallel-Group, Multi-Centre, Active-Controlled (Glibenclamide) Study to Evaluate the Efficacy, Safety and Tolerability of Tesaglitazar Therapy When Administered to Patients With Type 2 Diabetes
Sponsor: AstraZeneca
Terminated
The development program has been terminated
Other terminated trials from AstraZeneca
Other Type 2 Diabetes trials with similar outcome
A PHASE3 clinical study on Type 2 Diabetes, this trial is terminated or withdrawn. The trial is conducted by AstraZeneca and has accumulated 6 data snapshots since 2004. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Terminated PHASE3
First recorded
Sep 2004
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AstraZeneca
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Antwerp, Belgium , Arenzano, Italy , Balatonfüred, Hungary , Bangkok, Thailand , Bergen, Norway , Braine-l'Alleud, Belgium , Bratislava, Slovakia , Budapest, Hungary , Cape Town, South Africa , Changhua, Taiwan and 56 more locations